Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.

Article  PubMed  Google Scholar 

Kamran SC, D’Amico AV. Radiation therapy for prostate cancer. Hematol Oncol Clin North Am. 2020;34(1):45–69.

Article  PubMed  Google Scholar 

D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.

Article  PubMed  Google Scholar 

Punnen S, Cooperberg MR. The epidemiology of high-risk prostate cancer. Curr Opin Urol. 2013;23(4):331–6.

Article  PubMed  Google Scholar 

Burgess L, Aldrighetti CM, Ghosh A, Niemierko A, Chino F, Huynh MJ, et al. Association of the USPSTF Grade D recommendation against prostate-specific antigen screening with prostate cancer-specific mortality. JAMA Netw Open. 2022;5(5): e2211869.

Article  PubMed  PubMed Central  Google Scholar 

Butler SS, Muralidhar V, Zhao SG, Sanford NN, Franco I, Fullerton ZH, et al. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Cancer. 2020;126(4):717–24.

Article  CAS  PubMed  Google Scholar 

Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, Beard CJ, et al. Definition and validation of “favorable high-risk prostate cancer”: implications for personalizing treatment of radiation-managed patients. Int J Radiat Oncol Biol Phys. 2015;93(4):828–35.

Article  PubMed  Google Scholar 

Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066–73.

Article  CAS  PubMed  Google Scholar 

Thomsen FB, Brasso K, Christensen IJ, Johansson JE, Angelsen A, Tammela TL, et al. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study. Eur J Cancer (Oxford, England: 1990). 2015;51(10):1283–92.

Article  CAS  Google Scholar 

Fossa SD, Wiklund F, Klepp O, Angelsen A, Solberg A, Damber JE, et al. Ten- and 15-yr Prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of the Scandinavian Prostate Cancer Group-7. Eur Urol. 2016;70(4):684–91.

Article  PubMed  Google Scholar 

Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol. 2015;33(19):2143–50.

Article  PubMed  PubMed Central  Google Scholar 

Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92–02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26(15):2497–504.

Article  CAS  PubMed  Google Scholar 

Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360(24):2516–27.

Article  CAS  PubMed  Google Scholar 

Nabid A, Carrier N, Martin AG, Bahary JP, Lemaire C, Vass S, et al. Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial. Eur Urol. 2018;74(4):432–41.

Article  CAS  PubMed  Google Scholar 

Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza Rodriguez MA, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(3):320–7.

Article  CAS  PubMed  Google Scholar 

Butler SS, Dee EC, Lamba N, Sha ST, Mahal BA, Whitbeck A, et al. Validation of a subclassification for high-risk prostate cancer in a prospective cohort. Cancer. 2020;126(10):2132–8.

Article  CAS  PubMed  Google Scholar 

Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21(10):1904–11.

Article  PubMed  Google Scholar 

Lawton CA, DeSilvio M, Roach M 3rd, Uhl V, Kirsch R, Seider M, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94–13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007;69(3):646–55.

Article  PubMed  PubMed Central  Google Scholar 

Pommier P, Chabaud S, Lagrange JL, Richaud P, Le Prise E, Wagner JP, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys. 2016;96(4):759–69.

Article  PubMed  Google Scholar 

•• Murthy V, Maitre P, Kannan S, Panigrahi G, Krishnatry R, Bakshi G, et al. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol. 2021:Jco2003282. This study evaluated the potential benefit of whole-pelvic RT (WPRT) in high-risk prostate cancer using contemporary radiation techniques. This phase III trial randomized 224 patients to either WPRT or prostate-only RT with 2 years of ADT, finding that, with a median follow-up of 68 months, there was a biochemical failure-free survival benefit to WPRT (HR 0.23, 95%CI 0.10–0.52, p<0.0001) over prostate-only RT. This was similarly observed for the endpoints of disease-free survival (HR 0.40, 95%CI 0.22–0.73, p=0.002) and distant metastasis-free survival (HR 0.35, 95%CI 0.15–0.82, p=0.01).

Beckendorf V, Guerif S, Le Prisé E, Cosset JM, Bougnoux A, Chauvet B, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80(4):1056–63.

Article  PubMed  Google Scholar 

Dearnaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15(4):464–73.

Article  PubMed  Google Scholar 

Heemsbergen WD, Al-Mamgani A, Slot A, Dielwart MF, Lebesque JV. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014;110(1):104–9.

Article  PubMed  Google Scholar 

Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995;32(1):3–12.

Article  CAS  PubMed  Google Scholar 

Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):275–85.

Article  PubMed  Google Scholar 

Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, et al. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):286–95.

Article  PubMed  Google Scholar 

Oh J, Tyldesley S, Pai H, McKenzie M, Halperin R, Duncan G, et al. An updated analysis of the survival endpoints of ASCENDE-RT. Int J Radiat Oncol Biol Phys. 2023;115(5):1061–70.

Article  PubMed  Google Scholar 

Hoskin PJ, Rojas AM, Ostler PJ, Bryant L, Lowe GJ. Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results. Radiother Oncol. 2020;154:214–9.

Article  PubMed  Google Scholar 

De Bari B, Daidone A, Alongi F. Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature. Crit Rev Oncol Hematol. 2015;94(3):360–70.

Article  PubMed  Google Scholar 

Demanes DJ, Ghilezan MI. High-dose-rate brachytherapy as monotherapy for prostate cancer. Brachytherapy. 2014;13(6):529–41.

Article  PubMed  Google Scholar 

•• Kerkmeijer LGW, Groen VH, Pos FJ, Haustermans K, Monninkhof EM, Smeenk RJ, et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results From the FLAME Randomized Phase III Trial. J Clin Oncol. 2021:Jco2002873. This trial evaluated the potential benefit of a microboost to the visible intraprostatic lesion on mpMRI in high-risk prostate cancer patients. A total of 571 patients were randomized to receive radiation to the entire prostate +/- a simultaneous integrated focal boost up to 95 Gy to the intraprostatic lesion. After a median follow-up of 72 months, biochemical disease-free survival was significantly higher in the focal boost arm compared to the standard arm (HR 0.45, 95%CI 0.28–0.71, p<0.001) with no associated increased risk of GU toxicity.

Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, et al. Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the Randomized Phase III NRG Oncology RTOG 0521 Trial. J Clin Oncol. 2019;37(14):1159–68.

Sartor O, Karrison TG, Sandler HM, Gomella LG, Amin MB, Purdy J, et al. Androgen deprivation and radiotherapy with or without docetaxel for localized high-risk prostate cancer: long-term follow-up from the Randomized NRG Oncology RTOG 0521 Trial. Eur Urol. 2023;84(2):156–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Fransson AS, et al. Docetaxel versus surveillance after radical radiotherapy for intermediate- or high-risk prostate cancer-results from the prospective, randomised, open-label phase III SPCG-13 trial. Eur Urol. 2019;76(6):823–30.

Article  CAS  PubMed  Google Scholar 

• Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet (London, England). 2022;399(10323):447–60. This meta-analysis found that the addition of abiraterone acetate + oral prednisolone +/- enzalutamide to ADT in high-risk disease patients was associated with improvements in metastasis-free survival (HR 0.53, 95%CI 0.44-0.64, p<0.0001), prostate cancer-specific survival (HR 0.49, 95%CI 0.37-0.65, p<0.0001), and OS (HR 0.60, 95%CI 0.48-0.73, p<0.0001). There was no difference in metastasis-free survival when combining enzalutamide and abiraterone concurrently compared with abiraterone alone, although the combination of enzalutamide and abiraterone did result in additional toxicity, thus establishing that adding abiraterone to standard therapy with RT is appropriate for men with very high-risk prostate cancer.

Article  CAS  PubMed  Google Scholar 

Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet (London, England). 2019;394(10196):385–95.

Article  PubMed